|Bid||9.75 x 4000|
|Ask||12.86 x 900|
|Day's Range||11.70 - 13.19|
|52 Week Range||5.76 - 13.54|
|Beta (5Y Monthly)||2.42|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.00|
Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today reported financial results for the fourth quarter and full-year ended December 31, 2020 and recent program highlights.
This clinical-stage biotech is looking to make stem cell transplantation faster, easier, and safer for both donors and patients.
Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune and blood systems reset via stem cell transplant to more patients, today announced data presentations across its stem cell mobilization and targeted conditioning programs at the Transplantation and Cellular Therapy (TCT) Annual Meeting, to be held virtually on February 8-12, 2021.